BioCryst Pharmaceuticals(US:BCRX) Globenewswire·2025-10-20 11:00Core Viewpoint - BioCryst Pharmaceuticals will report its third quarter 2025 financial results on November 3, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Group 1: Financial Reporting - The third quarter 2025 financial results will be announced on November 3, 2025 [1]. - A conference call and webcast will take place at 8:30 a.m. ET on the same day to discuss the financial results [1]. Group 2: Access Information - Domestic callers can access the live call by dialing 1-844-481-2942, while international callers can dial 1-412-317-1866 [2]. - A live webcast and replay of the call will be available on the investors section of the company website [2]. Group 3: Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases [3]. - The company specializes in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics [3]. - BioCryst has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of therapies [3].